Macrogenics, CMC Biologics sign agreement to develop oncology product candidate

CMC Biologics, Inc., a global leader in process development and contract manufacturing, and MacroGenics, Inc.  (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, have entered into an agreement to further develop the production process for transfer and clinical manufacturing of one of MacroGenics' product candidates.

"We look forward to working with MacroGenics to further develop and advance this immuno-oncology program," said Gustavo Mahler, PhD, Global Chief Operations Officer of CMC Biologics. "This contract highlights CMC Biologics' focus on working with our customers as partners and our capabilities in the development and clinical manufacturing of monoclonal antibodies."

"We are impressed with CMC Biologics' experience and technical competency in biopharmaceutical development and cGMP manufacturing," said MacroGenics President and Chief Executive Officer, Scott Koenig, MD, PhD.  "Choosing a contract manufacturing partner with quality facilities that is able to provide flexible solutions and meet our clinical timelines is critical to realizing the potential of life-saving medicines."

SOURCE CMC Biologics